Pembrolizumab Injection Uses, Dosage, Side Effects and Interactions
Keytruda
Keytruda is a brand of pembrolizumab injection that comes as an injection.
Pembrolizumab Injection (Keytruda) is an intravenous immunotherapy used to treat many types of cancer, including melanoma, lung cancer, head and neck cancer, lymphomas, urothelial (bladder) cancer, and breast, cervical, kidney and endometrial cancers.
Quick links
Ask Anything About Pembrolizumab InjectionType a question in your own words. Answered from its FDA label in seconds.Every other section of this page is in the dots on the left edge of your screen: point at one to see where it goes.Every other section of this page is one tap away: use the arrow tab on the left edge of your screen.
Pembrolizumab Injection in Short
- Drug class Programmed Death Receptor-1 Blocking Antibody How the FDA classifies it
What it treatsKeytruda (pembrolizumab) is a PD-1-blocking antibody given by IV. It is approved for a wide range of cancers, often alongside chemotherapy or other cancer medicines, and sometimes on its own. Many uses require a tumor test first, such as PD-L1, MSI-H/dMMR or TMB-H status.
- How you get it Prescription only
- Comes asInjection (into a vein)
- Important safety informationWarnings and precautions Read the warnings and precautions for your exact product.
- Supplements and herbs1 interacts 1 minor, none major
The Pharmacist’s Take
Keytruda (pembrolizumab) is an IV immunotherapy for many cancers, including melanoma, lung, head and neck, and bladder cancers and Hodgkin lymphoma. It works by blocking PD-1, a switch tumors use to turn off immune cells, which releases the brakes on your immune response. On the market since about 2014, it has become one of the most widely used cancer drugs, with no biosimilar yet. Many people find it easier to tolerate than traditional chemotherapy, and tiredness, itchy rash, achy joints and loose stools are the most common complaints. The one thing to watch is the immune system attacking healthy organs, such as the lungs, bowel, liver or hormone glands, which can turn serious and can start anytime, even after treatment ends.
Key Takeaways From the HelloPharmacist Team
- Expect an IV infusion of about 30 minutes, given by your care team usually every 3 weeks or every 6 weeks.
- Call your team promptly about a new cough or breathlessness, diarrhea or belly pain, yellow skin or eyes, or unusual thirst.
- Expect blood tests before and during treatment to check your liver, kidneys and thyroid, which the drug can quietly inflame.
- Tell any doctor or emergency room you are on Keytruda, or were, since its immune side effects can look like ordinary illnesses.
Patient Information Guide for Pembrolizumab Injection
What It’s Used For
Keytruda (pembrolizumab, IV) is approved for many cancers. Specific uses depend on cancer type, stage, prior treatment and tumor testing.
- Melanoma that is unresectable or metastatic, and after complete surgery for stage IIB, IIC or III melanoma
- Non-small cell lung cancer, alone or with chemotherapy, before and after surgery, or after surgery and chemotherapy
- Malignant pleural mesothelioma, with chemotherapy
- Head and neck squamous cell cancer
- Classical Hodgkin lymphoma and primary mediastinal large B-cell lymphoma (not recommended for PMBCL needing urgent cytoreductive therapy)
- Urothelial cancer and bladder cancer, including muscle invasive and BCG-unresponsive non-muscle invasive disease
- MSI-H or dMMR solid tumors and colorectal cancer
- Gastric and gastroesophageal junction cancer, and esophageal cancer
- Cervical cancer
- Hepatocellular carcinoma related to hepatitis B, and biliary tract cancer
- Merkel cell carcinoma
- Renal cell carcinoma, with axitinib, lenvatinib or belzutifan, or alone after surgery
- Endometrial carcinoma
- TMB-H solid tumors
- Cutaneous squamous cell carcinoma
- Triple-negative breast cancer
- Ovarian cancer that is platinum-resistant, with paclitaxel
How It Works
Keytruda is a monoclonal antibody that binds to the PD-1 receptor on T cells. This blocks PD-1 from connecting with PD-L1 and PD-L2, which some tumors use to hide from the immune system. Blocking this frees your immune cells to mount a stronger attack on the cancer.
Drug Class
Drug Class
- Programmed Death Receptor-1 Blocking Antibody
Detailed classifications and sources
The FDA sorts a drug’s active ingredient by how it works, what it does in the body and its chemical structure, and gives it one main drug class.
Drug Class
Established Pharmacologic Class (EPC)- Programmed Death Receptor-1 Blocking Antibody
The main drug class the FDA gives it. It is the class named on the drug’s label.
How It Works
Mechanism of action (MoA)- Programmed Death Receptor-1-directed Antibody Interactions
What it does at the smallest level, such as a receptor or enzyme it blocks or switches on.
What It Does in the Body
Physiologic effect (PE)None listed for Pembrolizumab Injection in the FDA’s index.
From our Patient Information GuideKeytruda is a monoclonal antibody that binds to the PD-1 receptor on T cells. This blocks PD-1 from connecting with PD-L1 and PD-L2, which some tumors use to hide from the immune system. Read How Pembrolizumab Injection Works
A change it makes in how the body works.
Chemical Family
Chemical structure (CS)None listed for Pembrolizumab Injection in the FDA’s index.
The chemical family it belongs to, by its structure.
Drug Family
WHO ATC classification- PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors
How the World Health Organization groups it: by the part of the body it acts on and what it treats.
The classes are the FDA’s own words, from its index of drug labels, published in the National Library of Medicine’s RxClass. The description under What It Does in the Body is written by the HelloPharmacist team, not the FDA. Read the FDA’s definitions. The drug family is the World Health Organization’s ATC classification. Reference only, not medical advice.
Dosage
Keytruda is given by a healthcare professional as an IV infusion over about 30 minutes.
- Usually every 3 weeks or every 6 weeks, depending on your cancer and plan
- Children's dosing is based on body weight
- Length of treatment varies; it may continue until the cancer progresses, side effects are unacceptable, or a set time limit is reached
- If you miss an appointment, contact your care team to reschedule
Follow your prescriber and the label.
Typical Doses
Your prescriber chooses your dose, so take it exactly as prescribed.
Melanoma
For adults
Usual dose 200 mg every 3 weeks
- 200 mg every 3 weeks or 400 mg every 6 weeks
- Until disease progression or unacceptable toxicity
Cancer treatment after surgery (melanoma, lung cancer, kidney cancer)
Adults Usual dose 200 mg every 3 weeks
- 200 mg every 3 weeks or 400 mg every 6 weeks
- Until disease recurrence, unacceptable toxicity, or up to 12 months
Children 12 years and older Usual dose 2 mg/kg every 3 weeks Highest dose 200 mg
- 2 mg/kg every 3 weeks (up to a maximum of 200 mg)
- Until disease recurrence, unacceptable toxicity, or up to 12 months
Several cancers treated by itself
Adults Usual dose 200 mg every 3 weeks
- 200 mg every 3 weeks or 400 mg every 6 weeks
- Until disease progression, unacceptable toxicity, or up to 24 months
Children Usual dose 2 mg/kg every 3 weeks Highest dose 200 mg
- 2 mg/kg every 3 weeks (up to a maximum of 200 mg)
- Until disease progression, unacceptable toxicity, or up to 24 months
High-risk non-muscle invasive bladder cancer
For adults
Usual dose 200 mg every 3 weeks
- 200 mg every 3 weeks or 400 mg every 6 weeks
- Until persistent or recurrent high-risk NMIBC, disease progression, unacceptable toxicity, or up to 24 months
Lung cancer that can be removed by surgery
For adults
Usual dose 200 mg every 3 weeks
- 200 mg every 3 weeks or 400 mg every 6 weeks, given before chemotherapy when on the same day
- Neoadjuvant with chemotherapy for 12 weeks, then as a single agent after surgery for 39 weeks
Several cancers treated with chemotherapy
For adults
Usual dose 200 mg every 3 weeks
- 200 mg every 3 weeks or 400 mg every 6 weeks, given before chemotherapy when on the same day
- Until disease progression, unacceptable toxicity, or up to 24 months
Bladder and urinary tract cancer
For adults
Usual dose 200 mg every 3 weeks
- 200 mg every 3 weeks or 400 mg every 6 weeks, given after enfortumab vedotin-ejfv when on the same day
- Until disease progression, unacceptable toxicity, or up to 24 months
Muscle-invasive bladder cancer
Adults who can take cisplatin Usual dose 200 mg every 3 weeks
Step by step
- Neoadjuvant: 200 mg every 3 weeks for 4 doses or 400 mg every 6 weeks for 2 doses with enfortumab vedotin-ejfv
- Adjuvant: 200 mg every 3 weeks for 13 doses or 400 mg every 6 weeks for 7 doses with enfortumab vedotin-ejfv
Good to know
Cisplatin ineligibility: creatinine clearance of less than 60 mL/min, ECOG PS 2 or higher, Grade 2 or higher hearing loss, NYHA Class III or higher heart failure, or Grade 2 or higher peripheral neuropathy
Adults who cannot take cisplatin Usual dose 200 mg every 3 weeks
Step by step
- Neoadjuvant: 200 mg every 3 weeks for 3 doses with enfortumab vedotin-ejfv
- Adjuvant: 200 mg every 3 weeks for 14 doses or 400 mg every 6 weeks for 7 doses with enfortumab vedotin-ejfv
Head and neck cancer
For adults
Usual dose 200 mg every 3 weeks
- 200 mg every 3 weeks or 400 mg every 6 weeks, given before cisplatin when on the same day
- Neoadjuvant for 6 weeks, then adjuvant with RT with or without cisplatin, then as a single agent until recurrence, unacceptable toxicity or up to one year
Kidney cancer
For adults
Usual dose 200 mg every 3 weeks
- 200 mg every 3 weeks or 400 mg every 6 weeks with axitinib 5 mg orally twice daily or lenvatinib 20 mg orally once daily
- Until disease progression, unacceptable toxicity, or up to 24 months
Good to know
Axitinib dose escalation above 5 mg may be considered at intervals of six weeks or longer
Clear cell kidney cancer after surgery
For adults
Usual dose 200 mg every 3 weeks
- 200 mg every 3 weeks or 400 mg every 6 weeks with belzutifan 120 mg orally once daily
- Until disease recurrence, unacceptable toxicity, or up to 12 months
Side Effects
Common side effects when Keytruda is used alone include:
Common side effects
- Fatigue
- Muscle and joint pain
- Rash and itching
- Diarrhea
- Nausea
- Fever
- Cough and shortness of breath
- Decreased appetite
- Muscle and bone pain
- Constipation, nausea and belly pain
- Hypothyroidism (underactive thyroid)
When to get medical help
- Call your doctor right away for new or worsening cough, chest pain or shortness of breath, which could be lung inflammation (pneumonitis).
- Report diarrhea, severe belly pain or bloody stools, which could signal colitis (bowel inflammation).
- Tell your team about yellowing skin or eyes, dark urine or severe tiredness, which could signal liver inflammation.
- Report extreme tiredness, headaches, vision changes, or signs of high blood sugar such as unusual thirst and frequent urination, which can point to hormone gland problems or type 1 diabetes.
- Tell your team about changes in urination or swelling, which could signal kidney inflammation.
- Report fever, chills, flushing or breathing trouble during the infusion, which may be an infusion reaction.
- Immune side effects can appear at any time, even after treatment ends, so report new symptoms promptly.
With other cancer medicines, the side effects can differ and may include hair loss, nerve problems and low blood counts. Report severe or new symptoms, such as breathing problems, bad diarrhea, or yellow skin or eyes, right away.
Warnings and Precautions
- Immune-mediated reactions can be severe or fatal and may affect the lungs, bowel, liver, hormone glands, kidneys and skin. They can occur at any time, including after treatment ends.
- Infusion reactions may require slowing or stopping the infusion.
- Stem cell transplant complications can be fatal when transplant occurs before or after PD-1 blockers.
- Multiple myeloma: combining with a thalidomide analogue plus dexamethasone is not recommended outside clinical trials.
- Fetal harm is possible.
Interactions
The label highlights a few specific combinations to be careful with.
- Axitinib: higher rates of liver enzyme elevation, so liver tests are done more often
- Thalidomide analogue plus dexamethasone in multiple myeloma: not recommended outside trials
- Allogeneic stem cell transplant: risk of fatal and other serious complications
Not a complete list. The label covers the interactions the manufacturer studied or reported, and our own interaction database does not cover every medicine either. Bring your full medication list, including vitamins and herbal products, to your pharmacist.
Before You Start
- No contraindications are listed.
- Pregnancy: can cause fetal harm; pregnancy status is verified before starting and effective contraception is advised during treatment and for 4 months after the last dose.
- Breastfeeding: not advised during treatment and for 4 months after the last dose.
- Children: studied for certain cancers only; effectiveness in other uses has not been established.
- Older adults: generally similar results, though some groups had more serious side effects.
- Prior chest radiation, transplant history, or existing autoimmune or thyroid issues are worth discussing with your team.
Half-Life and How Your Body Processes It
Keytruda is given by IV, so it enters the bloodstream directly. Steady levels build up by about 16 weeks on an every-3-week schedule. Its half-life is about 22 days. Age, sex, mild to moderate liver impairment, kidney impairment and tumor size did not meaningfully change how the body clears it. The effect of severe liver impairment is unknown.
Storage
Store vials under refrigeration at 2°C to 8°C (36°F to 46°F) in original carton to protect from light. Do not freeze.
Written from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Supplements and Herbs That Interact With Pembrolizumab Injection
From the licensed clinical database we use, rolled up per supplement, most serious first.1 supplement and herbal product has documented interactions with Pembrolizumab Injection in the licensed clinical database we use.
Most are manageable, but your pharmacist should know about everything you take, including vitamins and herbals.
- 1Minor
Educational information from a licensed clinical database (Natural Medicines). See our data sources and update cadence. Not medical advice: an interaction being documented does not mean it will happen to you; do not start or stop medications or supplements without professional guidance.
Pembrolizumab Injection: Pharmacist Answers to Common Questions
Quick, plain-English answers to the questions patients ask most about Pembrolizumab Injection — the kind of thing our pharmacy team would talk through with you at the counter.
How is Keytruda given?
What happens if I miss a dose of Keytruda?
What side effects are common with Keytruda?
When should I call my doctor about side effects?
Is Keytruda safe during pregnancy or breastfeeding?
Will I need blood tests while on Keytruda?
Is pembrolizumab injection available over the counter?
When was pembrolizumab injection first available?
What is the brand name of pembrolizumab injection?
What is the generic name of Keytruda?
What drug class is pembrolizumab injection?
What strengths does pembrolizumab injection come in?
Where can I read the pembrolizumab injection prescribing information (package insert)?
Answers drafted from the FDA-approved label with AI and reviewed by our pharmacy team. How we use AI
Ask Anything About Pembrolizumab Injection
Skip the scrolling. Ask in your own words and get an answer from Pembrolizumab Injection’s FDA label and our pharmacists’ own work.
Name another drug or a supplement in your question and we check both.
AI answers from FDA labels and our own records, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.How this works
- Sources: Pembrolizumab Injection’s FDA label, including the clinical studies it reports, and the label of any drug you name; our pharmacists’ own work, such as our Do Not Crush list and our published answers to readers’ questions; our pharmacy prices and the Natural Medicines supplement database.
- Written by AI: Answers are written by AI from those sources, and AI can make mistakes. Check what you read here with your doctor or pharmacist before you act on it.
- Reviewed afterward: Our pharmacy team reviews every question and answer afterward to check it for accuracy, and when we find an error, we correct how the box answers. Read more in How we use AI.
- Not medical advice. In an emergency, call 911, Poison Control at 1-800-222-1222, or 988.
More About Pembrolizumab Injection on HelloPharmacist
Still have a question? A licensed pharmacist answers for free, usually within a day.Pembrolizumab Injection Forms and Strengths (How It Comes)
Pembrolizumab Injection comes in 1 dose form, the injection. Different forms and brands can have different approved uses, doses, schedules, and directions. Follow the instructions for your exact product, and do not switch forms without guidance from your prescriber or pharmacist.
Need a version that does not list lactose, a gluten source, a dye or gelatin? Inactive ingredients differ by manufacturer: see Pembrolizumab Injection inactive ingredients by manufacturer.
Injection
How this form is used
- Keytruda is used to treat melanoma, non-small cell lung cancer and head and neck squamous cell cancer.
- Keytruda is used for classical Hodgkin lymphoma, urothelial cancer, and breast, cervical, kidney and endometrial cancers.
- Keytruda is used for MSI-H/dMMR and TMB-H solid tumors that have progressed after prior treatment.
- Keytruda is given as an intravenous infusion over about 30 minutes after dilution.
- Keytruda is usually given every 3 weeks or every 6 weeks, depending on the cancer.
- Keytruda is given before chemotherapy when both are given on the same day.
Pembrolizumab Injection on the U.S. Market: Products, Makers and Brands
How Pembrolizumab Injection appears in the FDA’s National Drug Code Directory — including its dosage forms, strengths, brand names, manufacturers, and FDA-listed product records. These are directory records, not sales or prescription volume.
1 company lists 1 Pembrolizumab Injection product record with the FDA, mostly as injection; the earliest marketing or approval year on record is 2014. The one brand name in the directory today is Keytruda; the rest are generics.
Also listed with the FDA, not a patient dose form: Unfinished injection, solution (2) — bulk drug substance and unfinished product sold to compounders and other manufacturers to finish, and multi-item kits. These aren’t counted in the dose-form total above.
How Widely Pembrolizumab Injection Is Used (Medicaid Data)
How many Pembrolizumab Injection prescriptions Medicaid paid for in Q1–Q4 2025, every brand, strength and form together. Medicaid is one program, so total U.S. use is higher.
How commonly is Pembrolizumab Injection prescribed? Of the 1,682 medications we measure, Pembrolizumab Injection ranks #642 by Medicaid prescriptions — more than 62% of them.
Utilization by Pembrolizumab Injection product
Pick a strength and form to see its own numbers. Brand and generic versions are counted together.
4 ML pembrolizumab 25 MG/ML Injection
2 of 3 listed NDCs had Medicaid claims. RxNorm 1657750
Dollars are what Medicaid paid before the rebates drug makers send back, so its real cost is lower.
Source: Medicaid State Drug Utilization Data (CMS), all states. 2 of the 3 listed Pembrolizumab Injection NDCs had Medicaid claims.
Compare Pembrolizumab Injection Products
A representative set of FDA-listed product records for Pembrolizumab Injection — across manufacturers, strengths, and dosage forms, grouped by form with each product’s manufacturer and how the FDA approved it. The same medicine may be made and packaged by different companies, so a single drug can have many directory entries. (It’s also why a refill can look different — a new shape, color, or box — even though it contains the same medication.)
| Strength | Route | Manufacturer / Labeler | Category ⓘ | Details |
|---|---|---|---|---|
| 💊Injection | ||||
| 25 mg/mL | Intravenous | Merck Sharp & Dohme LLC | BLA | View NDC → |
Showing 1 of 1 products — FDA National Drug Code Directory. See every product, package size and price: browse all 1 Pembrolizumab Injection NDCs →
Pembrolizumab Injection Side Effects Reported to the FDA (FAERS)
After a medicine reaches the market, patients, doctors and drugmakers can send the FDA reports of problems they think may be linked to it. Here’s what’s been reported for Pembrolizumab Injection — a signal of what to watch for, not proof the drug caused it.
Source: openFDA, from the FDA Adverse Event Reporting System (FAERS). These are voluntary reports — they don’t prove the drug caused the effect, and counts reflect how often something was reported, not how often it actually happens. Reports also often name the very problem the medicine is taken for — a common reason to file one is that the drug didn’t help — so for a pain reliever you may see “pain” high on the list; that points to why the report was filed, not to the drug causing the symptom. This counts every report that lists Pembrolizumab Injection in any role, so the total runs higher than the FDA’s official dashboard, which counts only cases where the drug is the suspect. For the authoritative figures, see the FDA FAERS Public Dashboard. Always talk to your pharmacist or doctor.
Pembrolizumab Injection FDA Approval History
How Pembrolizumab Injection went from FDA review to the pharmacy shelf — the key milestones in its regulatory journey.
Source: Drugs@FDA.
Pembrolizumab Injection Recall History
A recall is when a specific batch of a medicine is pulled from the market — usually a manufacturing issue, not a problem with the drug itself. Class I is most serious, Class III least.
The FDA’s enforcement reports list no Pembrolizumab recalls since July 2021.
✅No Pembrolizumab recalls on record since July 2021Source: FDA enforcement (recall) reports, via openFDA; our copy was last updated Nov 19, 2026.
Pembrolizumab Injection in RxNorm: From Ingredient to Every Form and Strength
RxNorm is the U.S. National Library of Medicine’s standard name for every version of a medicine, the code pharmacy and prescribing systems share. This page starts from one ingredient (IN); each dose form (SCDF) branches from it, and each exact strength (SCD) from its form. Combination products are separate concepts with their own pages.
- Dose forms
- 1
- Strengths
- 2
- Forms in current FDA listings
- 1 of 1
RxCUI 1547545 -
Dose form (SCDF) InjectionIn current FDA listings
RxCUI 1657745Its 2 strengths (SCD)-
4 mL pembrolizumab 25 mg/mL
RxCUI 1657750 -
50 mg
RxCUI 1657746
-
4 mL pembrolizumab 25 mg/mL
RxNorm is the U.S. National Library of Medicine’s normalized drug vocabulary. Its concept hierarchy can include forms that are not currently marketed; the status on each branch compares that concept with current FDA listings. RxCUIs identify vocabulary concepts, not individual packages or manufacturers.
Pembrolizumab Injection Supply and Shortage Status
Whether Pembrolizumab Injection is in short supply in the U.S. right now, plus any shortage history the FDA has on record. A shortage usually reflects a manufacturing or demand issue — not a safety problem with the drug.
Source: openFDA, from the FDA Drug Shortages database.
Pembrolizumab Injection Brand Names
Pembrolizumab Injection has one brand name on record: Keytruda. A brand name is one company's name for the medicine; a generic has the same active ingredient under its generic name.
Who Makes Pembrolizumab Injection: Manufacturers and Labelers
One company lists Pembrolizumab Injection products with the FDA. By number of product records, the largest are Merck Sharp & Dohme LLC. Labelers include manufacturers and repackagers; the product in your bottle depends on which one your pharmacy stocks.
Sources for This Pembrolizumab Injection Page
Core label, product, RxNorm, safety, and utilization data on this page come from the sources identified below. AI-written, editorial, and licensed sections are labeled separately.
How this page is built
HelloPharmacist combines public FDA and NLM records and does not author the underlying clinical facts. The plain-language sections are written with AI from the FDA-approved label text and reviewed by our pharmacy team before publication. Merck Sharp & Dohme LLC is the representative DailyMed label linked for verification and dates. This is general education, not medical advice: always talk to your doctor or pharmacist about your own medicines. How we build and review drug pages →